INTRODUCTION INTRODUCTION INTRODUCTION INTRODUCTION INTRODUCTION
L avish in interpretations, the 60, (XX Century) coined the term "Polycystic Ovary Syndrome", applied to functional ovarian hyperandrogenism, incident in varying degree, both in the expression of cutaneous signs and in the levels of circulating androgens, influenced by the increase in insulin consecutive to glandular interrelationships that provide, from adolescence, endocrine fullness.
However, recent investigation procedures transcend the purely endocrine assumptions, so that they oppose the classic text, the description of Stein and Leventhal 1 , tied to the phenotypic heterogeneity that, from a clinical point of view, comprise, more often, menstrual irregularity, hirsutism and infertility. In the light of current knowledge, the polycystic ovary syndrome (PCOS) is extended and comprises an enormous field of intricate metabolic disturbances inherent to the broad concept of vascular disease.
Part of the diagnostic constitution, the development of dermal manifestations associated with PCOS is not exempt from questioning. Hormonal and metabolic factors interact in such a way that changes in homeostasis put themselves in line with the worsening of the aspects that comprise the dermatologic profile of PCOS. The important role of androgens, in spite of positive and negative associations with the skin condition, takes into account, the possibility of not detecting hyperandrogenemia.
Significant evidence points to the increased risk of type 2 diabetes in patients with PCOS 2 , whereas there is alleged cardiovascular involvement in long-term 3.4 . However, the prognosis is in summary expressed through the combination of risk factors that make up the concept of metabolic syndrome (MS), relevant to the careful assessment of PCOS, which is accompanied, as a rule, by the state of insulin resistance (IR) along with compensatory hyperinsulinemia. It is concluded that the timely recognition of patients likely to develop hypertension, altered glucose metabolism and atherosclerosis, among other parameters judged by greater severity, provides undeniable benefit in relation to the public health sphere.
This work aimed to establish the prevalence of MS and its clinical interrelationships with PCOS. Simultaneously, we tried to estimate the possible connection of MS with the adverse homeostatic condition of insulin resistance, obesity and the presence of acanthosis nigricans (AN), to reflect the impact attributed to PCOS as an early marker of cardiovascular disease.
METHODS
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One hundred patients affected by PCOS were selected in the Endocrine Gynecology Division of the Institute of Gynecology, Federal University of Rio de Janeiro (UFRJ).They were diagnosed by the Rotterdam criteria 5 and assisted in the period between April 2002 and May 2009, in a cross-sectional, prospective study. The clustering of cardiovascular risk factors entails the classification of MS according to the proposition of Grundy et al. 6 . The diagnosis is confirmed by the presence of at least three altered components including Type 2 diabetes. The description of the cutaneous examination, besides AN 7 , searched for hirsutism (score> 8) according to the modified criteria of Ferriman and Gallwey, Hatch et al. 8 , and for acne 9 . We defined amenorrhea as the absence of vaginal bleeding for more than six months and oligomenorrhea as menstrual intervals longer than 45 days. Irregular ovulation was detected between the 20th and the 24th days of the cycle by progesterone levels (< 3ng/ml) after two consecutive cycles. All patients with amenorrhea underwent ultrasonography, and when they had less than 5mm endometrial thickening they were subjected to hormonal dosages.
The clinical features evaluated were: age e" 16 years, weight (kg), height (m), body mass index (BMI) and measurement (cm) of waist circumference (WC) with nonelastic measure tape disposed between the bottom of the last rib and the superior border of the iliac crest, with the patient in upright position during expiration. The weight groups according to BMI were thus defined: Normal (18.5 kg/m 2 -24.9 kg/m 2 ), Overweight (25Kg/m 2 -30Kg/m 2 ) and obesity (> 30Kg/m 2 ). Blood pressure (mmHg) was measured in the right arm with the patient seated, after about ten minutes of rest.
Hormonal metabolic estimates, as well as transvaginal ultrasound (image interpreted according to the precepts of Balen et al. 10 ), were held between the third and seventh days of the menstrual cycle and blood collection (until 9 am) was preceded by fasting (12h). The HOMA-IR (homeostatic model assessment of insulin resistance) showed insulin sensitivity, with a cutoff e" 1.8 11 and measuring by HOMA Calculator 12 . The metabolic parameters were completed by serum fasting glucose, glycated hemoglobin and oral glucose tolerance test (OGTT). To evaluate fasting glucose, high sugar intolerance and to attest to the diabetic state, the criteria extracted from published reference 13 were used. Endocrine-metabolic research was complemented with the addition of hormonal parameters such as: FSH (follicle stimulating hormone), LH (luteinizing hormone), 17-hydroxyprogesterone, estradiol, prolactin, progesterone, cortisol, thyroid stimulating hormone (TSH) and insulin, whose levels have served to exclude other causes similar to the PCOS, as well as the estimation of testosterone, total and free, to complement the biochemical elements that lead to the diagnosis of PCOS. With regard to hormones, the process of ACS: 180 D Ciba-Corning Diagnostics chemiluminescence was used; insulin was measured by radioimmunoassay with gamma counter, and as for biochemistry, the appliances Selectraone or Express-plus were used.
The exclusion criterion concerned endocrine diseases and related conditions likely to cause direct or indirect disturbances of the menstrual cycle, which provide analogy or bond with PCOS. The restriction extended to the use of hormones 60 days prior to selection of patients. An identical precept was applied to medication usage, such as the calcium simvastatin and metformin, and substances that interfere with lipid metabolism. An anomalous LH / FSH ratio was not considered diagnosis principle of PCOS. We also excluded patients with a history of antibiotic treatment for more than one week in the last six months, habitual smoking and alcohol consumption, and drug addictions in general. Proven vascular (coronary or renal) disease was also an exclusion criterion.
Concerning statistical procedures, we took into account the gross amount, percentage, mean and standard deviation with the maximum and minimum values found (for continuous variables). We used the chi-square (÷2) test with the descriptive data for categorical variables. For the difference between the means of continuous variables (for different categories) we used the Student t test. The criterion adopted for the coefficient of significance (p < 0.05) corroborated the analysis. 
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Analysis of clinical data (Table 1) shows the patients' average around 25 years. While BMI and AC were predominant altered, normal weight comprised 35.6% of the measurements, and AC less than 80cm was present in 37.5% of patients.
Disorders of the menstrual cycle, as exposed, are common in PCOS. Thus, amenorrhea (63%) exceeded significantly oligomenorrhea (28%). MS affected 36% of patients, with a significant expression of only three altered components of the classification. Besides NA, cutaneous manifestations were restricted hirsutism and acne. The incidence of AN was greater than 95%, predominantly in the neck (posterior and lateral aspects), alone or in combination with other areas. AN rarely overcomes acne, even in small proportion, despite the strong presence of hirsutism, the usual predominant cutaneous manifestations of PCOS, in theory only surpassed in the clinical setting by oligomenorrhea. The incidences of hirsutism, acne and Ávila Ávila Ávila Ávila Ávila Polycystic ovary syndrome: implications of metabolic dysfunction AN were 72%, 49%, 53%, respectively. Statistical analysis showed no significant difference in the average age of groups with or without MS (Table 2 ). However, involvement by MS showed significant correlation with BMI, overpowered by the constitution of overweight and obesity, with AN, and in 51% of patients, with insulin resistance (HOMA-IR) . Moreover, the prevalence of cutaneous manifestations confer significance exclusively to AN combined with MS. The significant correlation restricted to AN is due to the predictable bond of the condition with IR and obesity. Despite more prevalent, amenorrhea did not display significant correlation with MS, similar to oligomenorrhea and normal menstrual cycle.
There was absence of type 2 diabetes with concomitant glucose intolerance in eight patients, which is attributed, at least in part, to the average age of the patients. However, regardless of the age factor, these findings demand routine inspection of the factors related to the cardiovascular risk supposed to increase with the metabolic disorder.
DISCUSSION DISCUSSION DISCUSSION DISCUSSION DISCUSSION
Insulin resistance seems to be the common factor responsible for the development or acceleration of many disorders that no rarely act together and for which it is proposed a variety of etiological mechanisms. In 1988, Reaven formalized the implications of IR along with glucose intolerance, lipid disorders and hypertension 14 . Such combinations maintain correspondence of cause and effect, Table 1  Table 1  Table 1  Table 1  Table 1 the different clinical aspects, as well as the inaccurate necessary adjustments amongst the different components arising, at least in part, from the impaired insulin action and the concomitant compensatory hyperinsulinemia. Furthermore, IR is considered the independent core engine of cardiovascular risk, diabetes being present or not. IR, mostly accompanied by hyperinsulinemia, alters homeostasis and contributes to cardiovascular risk mediated by the coexistence of the metabolic syndrome, which combines the classic stigmata of PCOS. Obesity and visceral fat accumulation tend to be more common when compared to other members of the diagnostic classifications.
We emphasize the autonomy of PCOS as avascular risk factor, especially in relation to type 2 diabetes, distinguishing convergence for diabetes and dyslipidemia regardless of BMI 20 . Experiments show that the persistence of symptoms related to the syndrome requires systematic research of diabetes despite unchanged fasting glucose. The irrelevance of hyperandrogenism in this scenario has also been observed. Regardless of the clinical manifestations of PCOS tend to wane with advancing age 21 due to the suppression of menstrual irregularity and hyperandrogenism, there still propensity to diabetes and consequent disorders 20, 22, 23 . In this context, an increase of 3.3 times has been documented in the increased risk of death from cardiovascular changes or myocardial infarction in postmenopausal women, when that intrinsic PCOS clinical features remain 24 . The prevalence of type 2 diabetes is increased in about eight times in PCOS patients 25 . And its deleterious effects are not restricted to the cardiovascular risks, with, the development of subclinical atherosclerosis and abnormal echocardiographic parameters, but include, likewise, abnormalities of the immune system, compatible with the low-grade chronic inflammation rendered by IR 26 . Analysis of this research demonstrates the impact of MS, which likely to be associated with the classical components of PCOS. The prevalence of MS ( 36%) is similar to previous data 2, 27, 28 , and to the latest 3, 29 . The significant coexistence with altered HOMA-IR corroborate this physiopathology.
On the other hand, the range of commitments inherent to the pathophysiology of PCOS comprises obesity, type 2 diabetes, and skin manifestations, AN being an important link with insulin resistance. The prevalence of AN, 53%, is noteworthy, sincd its significant association with MS has been described. Furthermore, the incidence of AN overcame the ones commonly reported 30 , largely predominant over acne.
Despite the MS interaction with PCOS, one must take into account the incipient metabolic dysfunction, as unraveled by the presence of various markers. Thus, the occurrence of anovulation and hyperandrogenism requires concurrent search for components that do not integrate the different clinical risk scores. It is proposed, therefore, irrespective of the age factor, the routine inspection for AN, the visible sign (sometimes subtle), associated with obesity, due to alleged coexistence with the invisible metabolic frame, both inherent to the phenotypic severity of PCOS inflicted in theory by IR.
Thus 
